Substituted imidazoles for the treatment of cancer

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 11434231
APP PUB NO 20200339554A1
SERIAL NO

16924157

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

There are provided compounds, their preparation and their use in the treatment of KRAS-driven cancers. The compounds according to the invention (general formula Class III) disrupt dimerization of KRAS and are inhibitors of KRAS mutants such as KRAS G12D, KRAS G12V and KRAS 12C. Embodiments of the compounds according to the invention are selective inhibitors of KRAS mutants over the wild-type (WT) KRAS.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARN

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Tian, Xiaohong Urumqi, CN 6 0
Wu, Jian Hui Saint-Laurent, CA 9 9
Yi, Qianhui Westmount, CA 2 0

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Mar 6, 2026
7.5 Year Payment $3600.00 $1800.00 $900.00 Mar 6, 2030
11.5 Year Payment $7400.00 $3700.00 $1850.00 Mar 6, 2034
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00